Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Haemodialysis, blood pressure and risk: at the limit of non-randomized evidence.

Ng SYA, Haynes R, Herrington WG.

Nephrol Dial Transplant. 2020 Mar 14. pii: gfaa043. doi: 10.1093/ndt/gfaa043. [Epub ahead of print] No abstract available.

PMID:
32170952
2.

In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes.

Ai Ng SY, Zhu D, Herrington WG.

Ann Intern Med. 2020 Feb 18;172(4):JC18. doi: 10.7326/ACPJ202002180-018. No abstract available.

PMID:
32066151
3.

Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals.

O'Lone E, Howell M, Viecelli AK, Craig JC, Tong A, Sautenet B, Herrington WG, Herzog CA, Jafar TH, Jardine M, Krane V, Levin A, Malyszko J, Rocco MV, Strippoli G, Tonelli M, Wang AY, Wanner C, Zannad F, Winkelmayer WC, Wheeler DC.

Nephrol Dial Transplant. 2020 Feb 10. pii: gfaa008. doi: 10.1093/ndt/gfaa008. [Epub ahead of print]

PMID:
32040154
4.

Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.

Lamprea-Montealegre JA, Staplin N, Herrington WG, Haynes R, Emberson J, Baigent C, de Boer IH; SHARP Collaborative Group.

Clin J Am Soc Nephrol. 2020 Jan 7;15(1):47-60. doi: 10.2215/CJN.07320619. Epub 2019 Dec 12.

PMID:
31831577
5.

Kidney disease trials for the 21st century: innovations in design and conduct.

Herrington WG, Staplin N, Haynes R.

Nat Rev Nephrol. 2020 Mar;16(3):173-185. doi: 10.1038/s41581-019-0212-x. Epub 2019 Oct 31. Review.

PMID:
31673162
6.

General and Abdominal Adiposity and Mortality in Mexico City: Prospective Study of 150 000 Adults.

Gnatiuc L, Alegre-Díaz J, Wade R, Ramirez-Reyes R, Tapia-Conyer R, Garcilazo-Ávila A, Chiquete E, Gonzáles-Carballo C, Solano-Sanchez M, Clarke R, Collins R, Herrington WG, Hill M, Lewington S, Peto R, Emberson JR, Kuri-Morales P.

Ann Intern Med. 2019 Aug 13. doi: 10.7326/M18-3502. [Epub ahead of print]

7.

Socioeconomic disadvantage and the risk of advanced chronic kidney disease: results from a cohort study with 1.4 million participants.

Weldegiorgis M, Smith M, Herrington WG, Bankhead C, Woodward M.

Nephrol Dial Transplant. 2019 Apr 23. pii: gfz059. doi: 10.1093/ndt/gfz059. [Epub ahead of print]

PMID:
31329936
8.

Chronic kidney disease, heart failure and neprilysin inhibition.

Haynes R, Zhu D, Judge PK, Herrington WG, Kalra PA, Baigent C.

Nephrol Dial Transplant. 2019 Apr 26. pii: gfz058. doi: 10.1093/ndt/gfz058. [Epub ahead of print]

PMID:
31028383
9.

In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.

Herrington WG, Zhu D, Haynes R.

Ann Intern Med. 2019 Feb 19;170(4):JC15. doi: 10.7326/ACPJ201902190-015. No abstract available.

PMID:
30776804
10.

Feasibility of Telemonitoring Blood Pressure in Patients With Kidney Disease (Oxford Heart and Renal Protection Study-1): Observational Study.

Warner BE, Velardo C, Salvi D, Lafferty K, Crosbie S, Herrington WG, Haynes R.

JMIR Cardio. 2018 Dec 21;2(2). pii: e11332. doi: 10.2196/11332.

11.

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C.

Clin Kidney J. 2018 Dec;11(6):749-761. doi: 10.1093/ckj/sfy090. Epub 2018 Oct 25. Review.

12.

Authors' Reply.

Herrington WG, Donovan K, Mihaylova B.

J Am Soc Nephrol. 2018 Oct;29(10):2602-2603. doi: 10.1681/ASN.2018060612. Epub 2018 Jul 13. No abstract available.

13.

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.

Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C.

Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818.

PMID:
30002098
14.

Change in Albuminuria and Risk of Renal and Cardiovascular Outcomes: Natural Variation Should Be Taken into Account.

Smith M, Herrington WG, Weldegiorgis M, Hobbs FR, Bankhead C, Woodward M.

Kidney Int Rep. 2018 Apr 16;3(4):939-949. doi: 10.1016/j.ekir.2018.04.004. eCollection 2018 Jul.

15.

Cardiovascular Outcomes Reported in Hemodialysis Trials.

O'Lone E, Viecelli AK, Craig JC, Tong A, Sautenet B, Roy D, Herrington WG, Herzog CA, Jafar T, Jardine M, Krane V, Levin A, Malyszko J, Rocco MV, Strippoli G, Tonelli M, Wang AYM, Wanner C, Zannad F, Winkelmayer WC, Webster AC, Wheeler DC.

J Am Coll Cardiol. 2018 Jun 19;71(24):2802-2810. doi: 10.1016/j.jacc.2018.04.012. Review.

16.

Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.

Marthi A, Donovan K, Haynes R, Wheeler DC, Baigent C, Rooney CM, Landray MJ, Moe SM, Yang J, Holland L, di Giuseppe R, Bouma-de Krijger A, Mihaylova B, Herrington WG.

J Am Soc Nephrol. 2018 Jul;29(7):2015-2027. doi: 10.1681/ASN.2017121334. Epub 2018 May 15. Review.

17.

Ezetimibe: Likely to Be Beneficial For All.

Herrington WG, Preiss D, Armitage J.

Circulation. 2018 Apr 10;137(15):1583-1584. doi: 10.1161/CIRCULATIONAHA.117.032819. No abstract available.

PMID:
29632152
18.

Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study.

Herrington WG, Alegre-Díaz J, Wade R, Gnatiuc L, Ramirez-Reyes R, Hill M, Solano-Sánchez M, Baigent C, Lewington S, Collins R, Tapia-Conyer R, Peto R, Kuri-Morales P, Emberson JR.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):455-463. doi: 10.1016/S2213-8587(18)30050-0. Epub 2018 Mar 19.

19.

Increasing the use of mobile technology-derived endpoints in clinical trials.

Herrington WG, Goldsack JC, Landray MJ.

Clin Trials. 2018 Jun;15(3):313-315. doi: 10.1177/1740774518755393. Epub 2018 Feb 5. No abstract available.

20.

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy.

Storey BC, Staplin N, Harper CH, Haynes R, Winearls CG, Goldacre R, Emberson JR, Goldacre MJ, Baigent C, Landray MJ, Herrington WG.

Kidney Int. 2018 May;93(5):1165-1174. doi: 10.1016/j.kint.2017.11.020. Epub 2018 Feb 12.

21.

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.

Storey BC, Staplin N, Haynes R, Reith C, Emberson J, Herrington WG, Wheeler DC, Walker R, Fellström B, Wanner C, Landray MJ, Baigent C; SHARP Collaborative Group.

Kidney Int. 2018 Apr;93(4):1000-1007. doi: 10.1016/j.kint.2017.09.011. Epub 2017 Nov 14.

22.

Extreme ischaemic heart disease risk in people with type 1 diabetes.

Herrington WG, Bragg F.

Heart. 2017 Nov;103(21):1656-1657. doi: 10.1136/heartjnl-2017-311553. Epub 2017 Jul 14. No abstract available.

PMID:
28710185
23.

Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.

Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V, Pfeffer MA, Rossing P, Walsh M, Wanner C, Wheeler DC, Winkelmayer WC, McMurray JJV; KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants.

Kidney Int. 2017 Aug;92(2):297-305. doi: 10.1016/j.kint.2017.04.019.

24.

The Role of Emerging Risk Factors in Cardiovascular Outcomes.

Lacey B, Herrington WG, Preiss D, Lewington S, Armitage J.

Curr Atheroscler Rep. 2017 Jun;19(6):28. doi: 10.1007/s11883-017-0661-2. Review.

25.

Biliary Tract and Liver Complications in Polycystic Kidney Disease.

Judge PK, Harper CHS, Storey BC, Haynes R, Wilcock MJ, Staplin N, Goldacre R, Baigent C, Collier J, Goldacre M, Landray MJ, Winearls CG, Herrington WG.

J Am Soc Nephrol. 2017 Sep;28(9):2738-2748. doi: 10.1681/ASN.2017010084. Epub 2017 May 2.

26.

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.

Reith C, Staplin N, Herrington WG, Stevens W, Emberson J, Haynes R, Mafham M, Armitage J, Cass A, Craig JC, Jiang L, Pedersen T, Baigent C, Landray MJ; SHARP Collaborative Group.

BMC Nephrol. 2017 May 1;18(1):147. doi: 10.1186/s12882-017-0545-2.

27.

Tightening our understanding of intensive glycaemic control.

Herrington WG, Preiss D.

Lancet Diabetes Endocrinol. 2017 Jun;5(6):405-407. doi: 10.1016/S2213-8587(17)30095-5. Epub 2017 Mar 30. No abstract available.

PMID:
28365412
28.

Body-mass index and risk of advanced chronic kidney disease: Prospective analyses from a primary care cohort of 1.4 million adults in England.

Herrington WG, Smith M, Bankhead C, Matsushita K, Stevens S, Holt T, Hobbs FD, Coresh J, Woodward M.

PLoS One. 2017 Mar 8;12(3):e0173515. doi: 10.1371/journal.pone.0173515. eCollection 2017.

29.

Adiposity and Blood Pressure in 110 000 Mexican Adults.

Gnatiuc L, Alegre-Díaz J, Halsey J, Herrington WG, López-Cervantes M, Lewington S, Collins R, Tapia-Conyer R, Peto R, Emberson JR, Kuri-Morales P.

Hypertension. 2017 Apr;69(4):608-614. doi: 10.1161/HYPERTENSIONAHA.116.08791. Epub 2017 Feb 21.

30.

The rise and rise of randomized clinical evidence in Sub-Saharan Africa.

Smyth B, Knight JF, Herrington WG.

Clin Kidney J. 2016 Dec;9(6):814-816. Epub 2016 Sep 9.

31.

Are statins useful in patients with advanced chronic kidney disease? - Authors' reply.

Herrington WG, Emberson J, Mihaylova B, Collins R, Baigent C; Cholesterol Treatment Trialists' Collaboration.

Lancet Diabetes Endocrinol. 2016 Dec;4(12):971-972. doi: 10.1016/S2213-8587(16)30266-2. No abstract available.

PMID:
27886746
32.

Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study.

Solbu MD, Mjøen G, Mark PB, Holdaas H, Fellström B, Schmieder RE, Zannad F, Herrington WG, Jardine AG.

Nephrol Dial Transplant. 2018 Jan 1;33(1):102-112. doi: 10.1093/ndt/gfw360.

PMID:
27798199
33.

Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP).

Staplin N, Herrington WG, Judge PK, Reith CA, Haynes R, Landray MJ, Baigent C, Emberson J.

Clin J Am Soc Nephrol. 2017 Mar 7;12(3):546-552. doi: 10.2215/CJN.02430316. Epub 2016 Aug 23.

34.

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.

Cholesterol Treatment Trialists' (CTT) Collaboration, Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellström B, Jardine AG, Wanner C, Holdaas H, Fulcher J, Haynes R, Landray MJ, Keech A, Simes J, Collins R, Baigent C.

Lancet Diabetes Endocrinol. 2016 Oct;4(10):829-39. doi: 10.1016/S2213-8587(16)30156-5. Epub 2016 Jul 29.

35.

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

Staplin N, Haynes R, Herrington WG, Reith C, Cass A, Fellström B, Jiang L, Kasiske BL, Krane V, Levin A, Walker R, Wanner C, Wheeler DC, Landray MJ, Baigent C, Emberson J; SHARP Collaborative Group.

Am J Kidney Dis. 2016 Sep;68(3):371-80. doi: 10.1053/j.ajkd.2016.02.052. Epub 2016 Apr 23.

36.

Effects of lowering LDL cholesterol on progression of kidney disease.

Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, Craig JC, de Zeeuw D, Feldt-Rasmussen B, Fellström B, Levin A, Wheeler DC, Walker R, Herrington WG, Baigent C, Landray MJ; SHARP Collaborative Group; SHARP Collaborative Group.

J Am Soc Nephrol. 2014 Aug;25(8):1825-33. doi: 10.1681/ASN.2013090965. Epub 2014 May 1.

38.

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).

Haynes R, Staplin N, Emberson J, Herrington WG, Tomson C, Agodoa L, Tesar V, Levin A, Lewis D, Reith C, Baigent C, Landray MJ; SHARP Collaborative Group.

Am J Kidney Dis. 2014 Jul;64(1):40-8. doi: 10.1053/j.ajkd.2013.12.013. Epub 2014 Mar 5.

39.

Metformin use in chronic kidney disease: new evidence to guide dosing.

Herrington WG, Nye HJ, Aung T.

QJM. 2013 Nov;106(11):1059-61. doi: 10.1093/qjmed/hct155. Epub 2013 Jul 10. No abstract available.

PMID:
23842484
40.

Does prophylactic anticoagulation reduce the risk of femoral tunneled dialysis catheter-related complications.

Herrington WG, Nye HJ, Haynes RJ, Winearls CG, Vaux EC.

J Vasc Access. 2013 Apr-Jun;14(2):135-42. doi: 10.5301/jva.5000117. Epub 2012 Nov 14.

PMID:
23172168
41.

Stroke risk in maintenance hemodialysis.

Herrington WG, Lewis DA.

Am J Kidney Dis. 2012 Jun;59(6):891; author reply 891-2. doi: 10.1053/j.ajkd.2012.02.338. No abstract available.

PMID:
22613396
42.

Kidney failure with a diagnostic chest radiograph.

Herrington WG, Lewis DA.

BMJ. 2012 Feb 3;344:e659. doi: 10.1136/bmj.e659. No abstract available.

PMID:
22306480
43.

Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis.

Herrington WG.

Neurology. 2011 Dec 6;77(23):2073; author reply 2073-4. doi: 10.1212/WNL.0b013e318239be24. No abstract available. Erratum in: Neurology. 2012 Feb 7;78(6):442.

PMID:
22146925
44.

Contraindications to pharmacologic therapies for gout.

Lewis DA, Herrington WG.

Am J Med. 2011 Oct;124(10):e15. doi: 10.1016/j.amjmed.2011.03.032. No abstract available.

PMID:
21962322
45.

Are arterial and venous samples clinically equivalent for the estimation of pH, serum bicarbonate and potassium concentration in critically ill patients?

Herrington WG, Nye HJ, Hammersley MS, Watkinson PJ.

Diabet Med. 2012 Jan;29(1):32-5. doi: 10.1111/j.1464-5491.2011.03390.x.

PMID:
21781155
46.

Metformin: the safest hypoglycaemic agent in chronic kidney disease?

Nye HJ, Herrington WG.

Nephron Clin Pract. 2011;118(4):c380-3. doi: 10.1159/000323739. Epub 2011 Feb 16. Review.

47.

Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma.

Herrington WG, Talbot DC, Lahn MM, Brandt JT, Callies S, Nagle R, Winearls CG, Roberts IS.

Am J Kidney Dis. 2011 Feb;57(2):300-3. doi: 10.1053/j.ajkd.2010.09.024. Epub 2010 Dec 21. Erratum in: Am J Kidney Dis. 2011 May;57(5):804.

PMID:
21177011
48.

Slowing the progression of chronic kidney disease.

Herrington WG, Mason PD.

Br J Hosp Med (Lond). 2009 Nov;70(11):634-8. Review.

PMID:
20081590
49.

The hyponatraemic hairdresser: highlighting the differentials.

Herrington WG, Al-Mossawi MH, Roberts IS, O'Callaghan CA.

Lancet. 2009 Oct 17;374(9698):1392. doi: 10.1016/S0140-6736(09)61198-3. No abstract available.

PMID:
19837256
50.

Metformin: effective and safe in renal disease?

Herrington WG, Levy JB.

Int Urol Nephrol. 2008;40(2):411-7. doi: 10.1007/s11255-008-9371-6. Review.

PMID:
18368503

Supplemental Content

Loading ...
Support Center